facilities the equipment and maintenance services of BMT Cluster center are to be 100% owned by the Skolkovo Foundation and its wholly owned subsidiary of Skolkovo Foundation Cluster BMT Centers for Shared Facilities (CSF) /Centers of Excellence (CeO)
15
Embed
Facilities the equipment and maintenance services of BMT Cluster center are to be 100% owned by the Skolkovo Foundation and its wholly owned subsidiary.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
facilities the equipment and maintenance services of BMT Cluster center are to be 100% owned by the Skolkovo Foundation and its wholly owned subsidiary of Skolkovo Foundation
Cluster BMT Centers for Shared Facilities
(CSF) /Centers of Excellence (CeO)
5 key elements of the innovation ecosystem of BMT
2
Community of BMT residents
InfrastructuresRegulatory environment
Institutes of commercialization
Training / Educational Programs
Ecosystem. 5
4 3
2
1
Business incubators Venture Capital Funds Strategic industrial investors Institutional Partners
Experts
Residents of the cluster (project companies)
Association of the resident’s partners (biomedical and pharmaceutical clusters)
Center for formalizing of IP Policy
Service Center of support of the Cluster residents (tax, legal, customs consultants)
Infrastructure link-laboratories
Centers for Shared Facilities (CSF), or Centers of Excellence (CoE)
R & D centers . Key partners
University (educational programs) International traineeship Internships International Conferences/Roadshows
22.05.2011 Confidential 3
Development CSF s. Why in 2011?
▪ CSFs are key elements of Skolkovo ecosystem. ▪ CSFs provide
▪ Infrastructural ground for collaboration with key-partners ▪ Integration of R&D, educational and commercialisation functions ▪ Effective use of Skolkovo budget by preparation the Skolkovo infrastructure for 2014 in 2011.
Effective use of the time required for the city construction. Training and preparation of qualified Skolkovo own professionals on Skolkovo own equipment
▪ Realisation of strategy approved by the SAC and the Board of Trustees. ▪ Collaborators worldwide and in Russia have been identified
▪ Most of big pharmaceutical and institutional investors (RVK, ROSNANO) expressed interest in CSFs ▪ Opportunity to involve Russian Ministry of Health as a major customer from 2011▪ A big time gap (half a year) between purchase, delivery, and installation of equipment in Russia. To be
able to use it Q1 2012 we need to order it now.▪ CSFs will become integral part of the University biomedical department or Techno park.
2014 2012 - 20132011
Infrastructural Link-Labs (Project based).
Centers for Shared Facilities (CSF) or CoE
Functioning of the BMT infrastructural Ecosystem
Educational programs based on the project companies community and infrastructure partners
Creation of Biomedical Department of Skolkovo University
Projects
Res
iden
ts
Infr
astr
uct
ure
s
Link-labs are based on project companies
activities
Part of the R & D centers establishes on the basis of Centers for
Shared FacilitiesR & D centers with key partners
Un
ive
rsit
y
Develop and implement the modules of special lectures and seminars (including "remote web – courses”)
Inv
es
tors
Re
gu
lato
ry
en
vir
on
me
nt
Co-investors and strategic projects partners
Venture Capital Funds
Institutional Partners (RUSNANO, RVC, VEB)
Creating a network of business incubators
Long-term relationships with strategic investors
Support by the functional units of the FundCreation of service centers of legal assistance based on
Techno park4
CSF development pipeline
21.05.2011 Confidential5
Basic Principles of CSF (CoE) functioning.
CSF research areas should be in the BMT foresights. CSF should provide services, research and educational programmes
1)
Capital expenses for major consumables and equipment are covered by the Fund. Operational budget to be provided by residents companies and external customers.
Infrastructure facilities, the equipment and maintenance services of CSFs are to be 100% owned by the Skolkovo Foundation or/and its wholly owned subsidiary.
3)
Project companies (residents of the Skolkovo Foundation) should have a first right to use CSFs services and competencies4)
CSF should provide and maintain excellence in access to modern biomedical equipment, research infrastructure, highly qualified staff, and services on the world level
5)
2)
Key Performance Indicators(KPI)
Budget of BMT Cluster Existing infrastructure sites (departments
of the universities, scientific research centers)
Project companies/residents of the Skolkovo Foundation
Needs and expectations of key partners (industrial biotech and pharmaceutical corporations), establishing of R&D centers
Existing partners of BMT Cluster
BMT sources KPIs for the BMT
Survey of existing infrastructure in Russia for priority areas (foresights)
Arrangement of a public tender. Choosing the best place /key partner for CSF
Identification of strategic partners (co-investors) to establish for CSF
Creation up to 10 CSFs Creation of 3 R&D centers with key partners,
based on CSF concept
21.05.2011 Confidential
Using existing competencies and adding novel ones.
Research and Development
Existing equipment New Equipment
CSF s(CoEs)
Existing methodologies and techniques
Staff Skills and experience
Commercialisation experience
Existing scientific collaborations
Project companies. CSF customers
New qualified staff
Key partners
Effective management
Innovation projectsEducational and retraining
programmes
7
Services
22.05.2011Confidential
8
CSFs address common needs in biotech and biomedicine processing and cover the most significant areas of competence
Early development Lead optimization Preclinical Clinical - Registration and launch
Transgenome and postgenome technologies
Foresightes: Biomedicineand Bio-pharmaceutics
Complex modeling and simulation. Biomedical Informatics
«Proteomics , and other omics
Preclinical and clinical studies. P4 Medicine. Cancer)
Planned CSF Competencies Major Collaborator Partners
Trans- and post- genome technologies
1. Recombinant human protein and antibodies production in animal cell cultures.
2. Development of new antibacterial drug based on recombinant proteins.
3. New strategies for anticancer therapies
Institute of Gene Biology, RAS
- ОАО «BinnoFarm» - CVT «ChemRar»- IMG RAN- Cold Spring Harbor Laboratory
(USA) - Waksman Institute (USA) - Ministry of health, Russia
Pre-clinical research. GLP standards
R&D and wide spectrum early (library synthesis, screening, hit-to-lead оoptimization) and late stage (toxicity, long term toxicity) pre-clinical studies using certified animals and high primates (CNS)
IBC RAS (Pushchino) - ОSC «RVC» - ITEB RAS (Pushchino) - Ministry of Health, Russia
Structural Biology. Membrane protein and their complexes
1. Cloning and expression of proteins. Membrane2. Protein purification. Membrane3. Protein crystallisation. Membrane.4. Complex structural analysis of proteins (X-RAY, NMR, neutrons)5. Modelling
MFTI and IBC RAS - Institute of Structural Biology (IBS, France) - EMBL, Grenoble - Research Centre (FZ-Juelich, Germany) - SCRIPPS Institute , (USA) - ONEKSIM GROUP
Centre for modelling in biomedicine
1. Modelling of the structure, mode of action and function of drugs2. Analysis, modelling and simulation of complex biological systems .
Virtual organisms.3. Biomedical informatics and databases4. Computer software for biomedical research5. Modelling and database on genomics, proteomics, metabolomics.
Techno park Skolkovo, IBMC RAMS
- IBMC RAMS - NOVARTIS AG - Astra Zeneca - МSU -Institute of Mathematics SO RAS (Novosibirsk) - Ural Cluster- Ministry of health, Russia
22.05.2011 10
CSFs development . Second Stage
Planned CSF Competencies Collaborators Partners
Pre clinical and clinical research for cancer and autoimmune diseases
1. Personalised profiling and analysis of cancer genomes2. Small purified RNAi 3. Combinatorial immunology with phage and cell libraries screening
IBC RAS - ОАО «PHARMSYNTEZ» - SCRIPPS Institute , (USA) - MSU - SpbMAPO RAMS- Dana Farber Cancer Centre, Harvard
Regenerative Medicine Development, testing and preclinical R&D based on novel stem cells technologies, which include among others Cardio Vascular diseasesNervous system pathologies with different aetiologyBone diseasesAging
Under Development
Proteomics Novel methods of analysis based on proteomics, peptidomics, metabolomics using human liquids in normal and disease states IBMC RAMS
- RSMU Sechenov under development
Synthetic Biology 1. Bioremediation2. Complex methods for directed evolution and 3. Industrial biotechnologies
MSU - University of Edinburgh - Massachusetts University - Okinawa Institute of Science and Technology -DIAGEO Inc. (GB)
22.05.2011 Confidential 11
CSFs. Training and further education programmes.
Planned CSF Planned programmes (Modules)
Trans and Post genome technologies
1. Cloning and mutagenesis2. RNA extraction RT-PCR, libraries creation, SELEX.3. Trans- genome technologies fro higher eukaryotes 4. Creation and screening of libraries5. Protein expression. Extraction methods for peptides and proteins6. Protein research in vivo7. Post translational modification for biopharmaceuticals
Pre clinical studies. GLP standards
1. Foundation for preclinical studies. Safety. 2. Laboratory animals for biomedical studies3. GLP standards
Structural biology 1. Molecular biology and expression of membrane proteins2. Structural biology, biophysics and physics. Membrane3. Crystallography and X-ray analysis4. NMR for protein and protein complexes
Modelling and Biomedical Informatics
1. Bioinformatics2. Systems Biology3. PK/PD , ADMET modelling4. Modelling of drug/target interactions
22.05.2011 Confidential 12
CSF. Basic structural Principles. Sectors and open infrastructure
CSF . Structural Biology. MFTI and IBC RAS
Target identification for structural analysis
Protein Cloning . MFTI-IBC
Expression and refolding. Membrane proteins(IBC)
Structural analysis. Membrane proteins
Protein crystallization. Membrane proteins
Protein purification. (MFTI-IBC)
X-RAY crystallography (MFTI)
Neutron structural analysis (MFTI)
NMR spectroscopy(IBC)
Confocal spectroscopy (MFTI)
Imaging (MFTI)
Computer modelling
Every SCF sector is a self sufficient entity and
can operate independently.
Sectors or/and laboratories could have separate
locations
Skolkovo owned Sectors/Laboratories are self
sufficient and could be re located to Skolkovo
premises in 2014 or earlier.
Modules in the sector have a status of a
standalone laboratory/Unit
CSF’s infrastructural elements developing TODAY creates the basis for FUTURE Innovation Center “Skolkovo”создают базу для будущего Инновационного Центра
2014 2012 - 20132011
IBMC RAMS
Concept and strategy approval
Biomedical Informatics. Modelling and simulation Centre
Creation of CSF
Creation of joint R&D centre with a key partner
Re-location and Integration to the Technopark Skolkovo
22.05.11 Confidential 13
Pre-clinical. GLP
Pushchino science Centre
Trans and post genomic technologies
Creation of joint R&D centre with a key partner
Exterritorial Integration to the Technopark Skolkovo
IBG RAS
Part of CSF sectors become laboratories at the Skolkovo University
Part of CSF sectors become exterritorial units of the Technopark Skolkovo.
Re-location and Integration to the Technopark Skolkovo and to the Skolkovo University
Structural biology. Membrane Proteins
MFTI and IBC RAS
22.05.2011 Confidential
14
CSF.Example. Scientific Councils
Skolkovo Foundation
SAC Skolkovo BMT Cluster
External expertsScientific council of major
partner(s)Scientific collaborators of
major partners(s)
Scientific Expert Council
CSF Scientific Council
Expert council of major partner(s)
CSF Development strategy Planning and management of R&D activities
Educational activities Collaboration with Russian and foreign partners
Example of CSF Scientific Council Composition
5 Skolkovo Fund representatives
5 Major partners representatives
2 Independent representatives
1 Chairman - independent. Elected
22/05.2011 Confidential 15
CSFs. Planned activities for 2011. Approved total budget for CFS = 1 287 353 thousands RR
CSF Main Partner may june july august
septemebr
octobernovemb
erTrans and post genome technologies IBG RAS
Preclinical. GLP stndards Pushchino
Structural Biology MFTI, IBC RASModelling and biomedical Informatics Centre Technopark
Concept approval, structuring, and hiring
Purchase of equipmentCSF launchProteomics IBCM RAMS Regenerative medicine TBDP4 Medicine. Cancer and autoimmune diseases IBC RASInfeection diseases IMB, MFTI, TBD "MAB" Generium, TBD Synthetic Biology MSU, TBD